LAUSR

Key Points Question Is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs glucagonlike peptide-1 receptor agonists (GLP-1 RAs) associated with dry eye disease among adults with type 2 diabetes (T2D)? Findings In this cohort study in Taiwan including 10 038 patients with T2D newly receiving SGLT2 inhibitors, there was a significant risk reduction in the incidence of dry eye diseases compared with 1077 propensity score–weighted patients with T2D newly receiving GLP-1 RAs. The lower dry eye disease incidence with use of SGLT2 inhibitors was consistent across different subgroup and sensitivity analyses. Meaning The findings of this study suggest that patients with T2D newly receiving SGLT2 inhibitors may experience a lower risk for dry eye disease compared with those receiving GLP-1 RAs.